A detailed history of Raymond James & Associates transactions in Foghorn Therapeutics Inc. stock. As of the latest transaction made, Raymond James & Associates holds 2,297,319 shares of FHTX stock, worth $11.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,297,319
Previous 2,338,423 1.76%
Holding current value
$11.5 Million
Previous $13.4 Million 59.08%
% of portfolio
0.01%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

SELL
$4.8 - $9.99 $197,299 - $410,628
-41,104 Reduced 1.76%
2,297,319 $21.4 Million
Q2 2024

Jul 19, 2024

BUY
$5.05 - $8.0 $545,233 - $863,736
107,967 Added 4.84%
2,338,423 $13.4 Million
Q1 2024

Apr 22, 2024

BUY
$2.82 - $7.94 $457,034 - $1.29 Million
162,069 Added 7.84%
2,230,456 $15 Million
Q4 2023

Jan 16, 2024

BUY
$2.94 - $6.76 $1.89 Million - $4.34 Million
642,161 Added 45.03%
2,068,387 $13.3 Million
Q3 2023

Oct 24, 2023

BUY
$5.0 - $9.87 $1.18 Million - $2.32 Million
235,237 Added 19.75%
1,426,226 $7.13 Million
Q2 2023

Jul 25, 2023

BUY
$5.37 - $8.84 $606,450 - $998,327
112,933 Added 10.48%
1,190,989 $8.38 Million
Q1 2023

Apr 14, 2023

BUY
$4.66 - $8.99 $2.48 Million - $4.79 Million
533,123 Added 97.83%
1,078,056 $6.68 Million
Q4 2022

Feb 08, 2023

BUY
$5.44 - $9.46 $2.81 Million - $4.88 Million
515,796 Added 1770.24%
544,933 $3.48 Million
Q3 2022

Oct 25, 2022

BUY
$7.52 - $18.01 $7,520 - $18,010
1,000 Added 3.55%
29,137 $250,000
Q2 2022

Aug 12, 2022

BUY
$8.48 - $16.84 $16,960 - $33,680
2,000 Added 7.65%
28,137 $383,000
Q1 2022

May 11, 2022

BUY
$8.87 - $22.1 $117,083 - $291,720
13,200 Added 102.03%
26,137 $398,000
Q4 2021

Feb 08, 2022

BUY
$10.79 - $22.87 $139,590 - $295,869
12,937 New
12,937 $296,000

Others Institutions Holding FHTX

About Foghorn Therapeutics Inc.


  • Ticker FHTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,637,400
  • Market Cap $209M
  • Description
  • Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines targeting genetically determined dependencies within the chromatin regulatory system. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It is developing FHD-28...
More about FHTX
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.